Mohammad Haddadi: New Insights on Chronic Histiocytic Intervillositis Outcomes
Mohammad Haddadi, Medical Doctor at Aflatoon Clinic, shared a post on LinkedIn about a paper published in International Journal of Gynecological Pathology:
“Proud to share our latest publication in the International Journal of Gynecological Pathology, ‘Placental Chronic Histiocytic Intervillositis: Pregnancy Outcomes and Complications – A Systematic Review and Meta-Analysis’.
Chronic histiocytic intervillositis (CHI) is a rare but serious placental inflammatory condition with profound implications for pregnancy outcomes. In this systematic review and meta-analysis, we synthesized evidence from 12 studies encompassing 568 pregnancies to better quantify maternal and neonatal risks associated with idiopathic CHI.
Key findings:
- 40% pooled frequency of intrauterine growth restriction (IUGR)
- 55% live birth rate
- 20% intrauterine fetal death (IUFD)
- Findings remained consistent in sensitivity analyses restricted to low-risk studies
Our results highlight the substantial burden of adverse outcomes associated with CHI and reinforce the need for early recognition, standardized diagnostic criteria, and targeted management strategies in affected pregnancies.
Grateful to work with an excellent team of collaborators. Looking forward to seeing how these findings contribute to improved placental pathology awareness and maternal–fetal care.
Link.”
Title: Placental Chronic Histiocytic Intervillositis: Pregnancy Outcomes and Complications, a Systematic Review and Meta-Analysis
Authors: Elena Ghotbi, Zeinab Mansouri, Alireza Azarboo, Nasim Eshraghi, Marjan Ghaemi, Mohammad Haddadi, Zahra Panahi, Sedigheh Hantoushzade
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Nov 2, 2026, 17:08Elena Milner: The 2nd Class of the School of Embryology Is Already in Full Swing
-
Nov 2, 2026, 17:05November Is National Diabetes Month – PCOS Awareness Association
-
Nov 2, 2026, 17:04Thanos Papathanasiou: Are We Preparing Patients for the IVF Cycle, or for the IVF Journey?
-
Nov 2, 2026, 17:02Anna Morales: Why Is It So Hard to Build in Women’s Health?
-
Nov 2, 2026, 16:59Rickard Ericsson: Honored to Take on the Role of Interim CEO of the Vitrolife Group
-
Nov 2, 2026, 16:56Mohammed Nasur: 1 Small Simulation, A Bigger Purpose
-
Nov 2, 2026, 16:54Carlos Guerrero: Presenting Our Latest Research on AI and Embryo Assessment at ASRM 2026
-
Nov 2, 2026, 16:52Sarah Lewen: My 1st ASRM Is Officially Complete
-
Nov 2, 2026, 16:49Jemma Garratt: Taking on the Role of Kind IVF and Data Science Manager at London Women’s Clinic